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E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3 43Conclusion: ErbB-inhibitors represent a new therapeutic
approach in MM. A clinical trial testing the ErbB1-inhibitor cetux-
imab and correlating response with the expression of ErbB-recep-
tors/ligands is in preparation at the University Hospitals of
Cologne, Heidelberg and Montpellier.
doi:10.1016/j.ejcsup.2006.04.103
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Background: Malignant melanoma, notorious for its poor
response to currently available therapeutics, is one of the fastest
increasing cancers. Therefore, development of new alternative
treatment strategies (including immunotherapeutic ones) is
extremely important. This approach requires an establishment
of the reliable animal melanoma model that resembles human
melanoma with respect to etiology, tumor genetics, histopathol-
ogy and clinical development. We use a recently developed mouse
model of spontaneous skin melanoma, in which ret transgene (tg)
is expressed in melanocytes under the control of metallothio-
nein-I promoter (MT/Ret). Activity of the receptor tyrosine kinase,
Ret, is upregulated during the disease progression.
Methods: Immunohistology, flow cytometry, ELISPOT, ELISA, tet-
ramer staining and in vivo kill.
Results: After a short latency (2–4 months), around 30% of mice
develop skin melanoma metastasizing to lymph nodes, lungs and
brain. We found that tumors expressed melanoma associated
antigens tyrosinase, tyrosinase related protein (TRP)-1, TRP-2
and gp100, which could be applied as targets for the immunother-
apy. Ret-tg mice without tumors could mount both antigen-
unspecific (stimulation with Con A or with CD3/CD28 antibodies)
and antigen-specific (ovalbumin or TRP-2 derived peptide) T-cell
reactions, which were downregulated in melanoma bearing Ret-
tg mice. In addition, Ret-tg mice have more effector memory
and regulatory T cells than healthy (wild type) mice.
Conclusion: New strategies of melanoma immunotherapy in
this spontaneous melanoma mouse model (including therapy
with memory T cells together with dendritic cells or depletion
of regulatory T cells) will be discussed.
doi:10.1016/j.ejcsup.2006.04.104
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Background: Protein kinase (PK) inhibitors are candidates for
modifying the response of tumour cells to anticancer agents suchas radiotherapy. The purpose of the present study was to compare
inhibition of the PI3K/Akt survival pathway by specific concentra-
tions of different PK inhibitors with changes in the radiosensitiv-
ity of glioblastoma cell lines in vitro.
Methods: Glioblastoma cell lines U343MG, U87MG and U251MG
were used. PI3K inhibitors (Wortmannin; LY294002) and receptor
tyrosine kinase (RTK) inhibitors (AG1296; AG1478; erlotinib) were
added to cultures before or after irradiation. The phosphorylation
state of Akt was detected by Western blotting. The cellular radio-
sensitivity was measured by the colony formation assay fitting
survival curves with the linear-quadratic model.
Results: The inhibitory effect of Wortmannin and LY294002 on
Akt phosphorylation depended on the cell line. However, whereas
downregulation to a variable degree was observed with 50 nM
Wortmannin, radiosensitization required micromolar concentra-
tions. RTK inhibitors had little influence on Akt phosphorylation
but moderately sensitised cells to radiation. However, the sensi-
tising effect was similar whether the inhibitor was added before
or after irradiation.
Conclusions: The results did not support a correlation between
radiosensitisation and inhibition of the PI3K/Akt survival path-
way. RTK inhibitors were not required to be present during irradi-
ation in order to sensitise cells and thus cannot be considered
classical radiosensitisers. Instead they may exert their inhibitory
effect on clonogenicity. We further conclude that signal transduc-
tion differs between glioblastoma cell lines and propose that this
might have prognostic value in vivo.
doi:10.1016/j.ejcsup.2006.04.105
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Introduction: The centrosome is a small organelle which con-
sists of two centrioles and the pericentriolar matrix. It functions
as the microtubule-organizing center of eukaryotic cells and plays
a central role in chromosome segregation and cytokinesis. Many
human malignancies harbor centrosomal aberrations, which are
caused by deregulation of centrosome duplication or cytokinesis
failure. Cells with supernumerary centrosomes usually form mul-
tipolar spindles leading to aberrant mitoses with consecutive
chromosome missegregation. To regain secondary karyotype sta-
bility after clonal selection, some tumor cells coalesce their extra
centrosomes by a poorly defined mechanism into two spindles
poles in order to divide properly.
Method: Here, we describe an automated screening strategy
designed to identify small molecules – produced by hundreds of
